Digest Network How does it work
Network
/
Society
Ar
Not verified

Arialys Therapeutics

What we write about

BiotechnologyHealthIndustriaPharmaceuticalsPsychiatry

6 Press releases

View all press releases
25/09/2025
Industria
Psychiatry
Health
HIV, AIDS and autoimmune disorders
Pharmaceuticals
Biotechnology
Arialys Therapeutics Receives FDA Rare Pediatric Disease Designation for ART5803 to Treat Anti-NMDA Receptor Encephalitis
Source
Arialys Therapeutics
Issuer
Business Wire
1.00
0
17/06/2025
Psychiatry
Scienza
Medicine - various
Biotechnology
Health
Pharmaceuticals
Sanità
Industria
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
Source
Arialys Therapeutics
Issuer
Business Wire
1.00
0
26/02/2025
Biotechnology
Sanità
Health
Pharmaceuticals
Psychiatry
Scienza
Medicine - various
Industria
Arialys Therapeutics Initiates MAD Cohorts Having Completed All Planned SAD Cohorts in a Phase 1 Study of ART5803 for the Treatment of Autoimmune Neuropsychiatric Disease
Source
Arialys Therapeutics
Issuer
Business Wire
1.00
0
22/10/2024
Labour market
Psychiatry
Scienza
Biotechnology
Sanità
Health
Pharmaceuticals
Arialys Therapeutics Appoints Sankalp Gokhale, M.D., Chief Medical Officer
Source
Arialys Therapeutics
Issuer
Business Wire
1.00
0
10/10/2024
Psychiatry
Health
Medicine - various
Pharmaceuticals
Biotechnology
Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune Neuropsychiatric Diseases
Source
Arialys Therapeutics
Issuer
Business Wire
1.00
0
25/06/2024
Biotechnology
Psychiatry
Health
Pharmaceuticals
Labour market
Arialys Therapeutics Appoints Peter Flynn, Ph.D., President and Chief Executive Officer
Source
Arialys Therapeutics
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0